SAN DIEGO, CA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage medical technology company focused on addressing unmet needs in global ...
Sigyn Therapy™ demonstrates the ability to address viral pathogens, including SARS-CoV-2 (COVID-19) SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Sigyn Therapeutics, Inc.
Sigyn Therapy™ is a Candidate to Treat Sepsis and Other Life-Threatening Inflammatory Conditions That Are Not Addressed with Approved Drugs Sigyn Therapy is a novel blood purification technology ...
Aside from ongoing COVID infections and one of the deadliest influenza seasons in a quarter century, the range of life-threatening viruses endangering humans continues to expand. Failure to contain ...
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory ...
SAN DIEGO, CA, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory ...
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address ...
Sigyn Therapeutics Inc. Annual stock financials by MarketWatch. View the latest SIGY financial statements, income statements and financial ratios.
Sigyn Therapy™ demonstrates the ability to address viral pathogens, including SARS-CoV-2 (COVID-19) Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results